The whole world of gambling is on your smartphone with the Mostbet app - join us!
Home  »  Companies   »  Iovance Biotherapeutics Inc. (IOVA): A Technical A...

Iovance Biotherapeutics Inc. (IOVA): A Technical Analysis

compared to its average ratio and a 36-month beta value of 0.10. Analysts have mixed views on the stock, with 10 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”

The average price point forecasted by analysts for Iovance Biotherapeutics Inc. (IOVA) is $22.36, which is $18.98 above the current market price. The public float for IOVA is 232.91M, and currently, short sellers hold a 12.91% ratio of that float. The average trading volume of IOVA on September 15, 2023 was 5.08M shares.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


IOVA) stock’s latest price update

The stock of Iovance Biotherapeutics Inc. (NASDAQ: IOVA) has increased by 19.92 when compared to last closing price of 4.64.Despite this, the company has seen a loss of -6.38% in its stock price over the last five trading days. Zacks Investment Research reported 2023-09-15 that Iovance (IOVA) rises despite the FDA’s postponement of the decision date regarding the regulatory filing for its lead candidate, lifileucel, to treat advanced melanoma due to resource constraints.

IOVA’s Market Performance

Iovance Biotherapeutics Inc. (IOVA) has seen a -6.38% fall in stock performance for the week, with a -19.27% decline in the past month and a -35.53% plunge in the past quarter. The volatility ratio for the week is 10.80%, and the volatility levels for the past 30 days are at 6.46% for IOVA. The simple moving average for the past 20 days is -7.16% for IOVA’s stock, with a -19.54% simple moving average for the past 200 days.

Analysts’ Opinion of IOVA

Many brokerage firms have already submitted their reports for IOVA stocks, with Wells Fargo repeating the rating for IOVA by listing it as a “Overweight.” The predicted price for IOVA in the upcoming period, according to Wells Fargo is $17 based on the research report published on May 30, 2023 of the current year 2023.

IOVA Trading at -18.74% from the 50-Day Moving Average

After a stumble in the market that brought IOVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.11% of loss for the given period.

Volatility was left at 6.46%, however, over the last 30 days, the volatility rate increased by 10.80%, as shares sank -12.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.68% lower at present.

During the last 5 trading sessions, IOVA fell by -8.07%, which changed the moving average for the period of 200-days by -8.07% in comparison to the 20-day moving average, which settled at $5.96. In addition, Iovance Biotherapeutics Inc. saw -12.83% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at IOVA starting from MCPEAK MERRILL A, who purchase 10,000 shares at the price of $6.15 back on Dec 21. After this action, MCPEAK MERRILL A now owns 70,150 shares of Iovance Biotherapeutics Inc., valued at $61,500 using the latest closing price.

Rothbaum Wayne P., the Director of Iovance Biotherapeutics Inc., purchase 10,000,000 shares at $6.50 during a trade that took place back on Dec 02, which means that Rothbaum Wayne P. is holding 18,067,333 shares at $65,000,000 based on the most recent closing price.

Stock Fundamentals for IOVA

Equity return is now at value -78.30, with -60.00 for asset returns.


To put it simply, Iovance Biotherapeutics Inc. (IOVA) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.